Optimizing resource allocation in United States AIDS drug assistance programs

被引:9
作者
Linas, Benjamin P.
Zheng, Hui
Losina, Elena
Rockwell, Annette
Walensky, Rochelle P.
Cranston, Kevin
Freedberg, Kenneth A.
机构
[1] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Harvard Ctr AIDS Res, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Dept Biostat, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA 02115 USA
[6] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA
[7] Massachusetts Dept Publ Hlth AIDS Bur, Boston, MA USA
关键词
D O I
10.1086/508657
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. US acquired immunodeficiency syndrome (AIDS) Drug Assistance programs (ADAPs) provide medications to low-income patients with human immunodeficiency virus ( HIV) infection/AIDS. Nationally, ADAPs are in a fiscal crisis. Many states have instituted waiting lists, often serving clients on a first-come, first-served basis. We hypothesized that CD4 cell count-based ADAP eligibility would improve ADAP outcomes, allowing them to serve more-diverse patient populations and to prioritize persons who are at greatest risk of HIV-related mortality. Methods. We used Massachusetts ADAP administrative data to create a retrospective cohort of Massachusetts ADAP clients from fiscal year 2003. We then used a model-based analysis to apply potential eligibility criteria for a limited program and to compare characteristics of patients included under CD4 cell count-based and first-come, first-served eligibility criteria. Results. In fiscal year 2003, Massachusetts ADAPs served 3560 clients at a direct cost of $10.3 million. With use of CD4 cell count-based eligibility (with an eligibility criterion of a current or nadir CD4 cell count <= 350 cells/mu L), it would have served 2253 clients (37% fewer than in fiscal year 2003) and appreciated savings of $2.7 million. Given the same budget constraint and using first-come, first-served eligibility, Massachusetts ADAPs would have served 2406 clients (32% fewer than in fiscal year 2003). The first-come, first-served approach would have excluded patients with median CD4 cell count of 257 cells/mu L (interquartile range, 124-377 cells/mu L) in favor of serving patients with median CD4 cell count of 659 cells/mu L (interquartile range, 511-841 cells/mu L). In addition, a CD4 cell count-based scheme would have served a greater proportion of nonwhite individuals (65% vs. 55%;), non-English speakers (24% vs. 19%;), and unemployed people (69% vs. 61%;), P <.0001 Pp. 03 Pp. 0009 compared with the population that would have been served by a first-come, first-served policy. Conclusions. With limited resources, ADAPs will serve more- diverse populations and patients with significantly more advanced HIV disease by using CD4 cell count-based enrollment criteria rather than a first-come, first-served approach.
引用
收藏
页码:1357 / 1364
页数:8
相关论文
共 27 条
[1]  
Andersen R, 2000, HEALTH SERV RES, V35, P389
[2]   Ethnic differences in. stage of presentation of adults newly diagnosed with HIV-1 infection in south London [J].
Boyd, AE ;
Murad, S ;
O'Shea, S ;
de Ruiter, A ;
Watson, C ;
Easterbrook, PJ .
HIV MEDICINE, 2005, 6 (02) :59-65
[3]   Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. [J].
Bozzette, SA ;
Joyce, G ;
McCaffrey, DF ;
Leibowitz, AA ;
Morton, SC ;
Berry, SH ;
Rastegar, A ;
Timberlake, D ;
Shapiro, MF ;
Goldman, DP .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :817-823
[4]   Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models [J].
Cole, SR ;
Hernán, MA ;
Robins, JM ;
Anastos, K ;
Chmiel, J ;
Detels, R ;
Ervin, C ;
Feldman, J ;
Greenblatt, R ;
Kingsley, L ;
Lai, SH ;
Young, M ;
Cohen, M ;
Muñoz, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (07) :687-694
[5]   Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women [J].
Cook, JA ;
Cohen, MH ;
Grey, D ;
Kirstein, L ;
Burke, J ;
Anastos, K ;
Palacio, H ;
Richardson, J ;
Wilson, TE ;
Young, M .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2002, 92 (01) :82-87
[6]  
CROSSE M, 2006, AIDS DRUG ASSISTANCE
[7]   Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States [J].
Cunningham, WE ;
Markson, LE ;
Andersen, RM ;
Crystal, SH ;
Fleishman, JA ;
Golin, C ;
Gifford, A ;
Liu, HHH ;
Nakazono, TT ;
Morton, S ;
Bozzette, SA ;
Shapiro, MF ;
Wenger, NS .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) :115-123
[8]   Fair process in patient selection for antiretroviral treatment in WHO's goal of 3 by 5 [J].
Daniels, N .
LANCET, 2005, 366 (9480) :169-171
[9]   RATIONING FAIRLY - PROGRAMMATIC CONSIDERATIONS [J].
DANIELS, N .
BIOETHICS, 1993, 7 (2-3) :224-233
[10]  
Daniels Norman, 2001, American Journal of Bioethics, V1, P2, DOI 10.1162/152651601300168834